EMEA-002530-PIP01-18
Key facts
| Active substance |
atogepant
|
| Therapeutic area |
Pain
|
| Decision number |
P/0046/2020
|
| PIP number |
EMEA-002530-PIP01-18
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Prevention of migraine headaches
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Allergan Pharmaceuticals International Limited
E-mail: ml-eu_reg_affairs@allergan.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|